Exela Pharma Sciences LLC

Exela Pharma Sciences LLC, founded in 2005, is a rapidly expanding specialty pharmaceutical company with a mission to enhance lives "With Passion." The company is dedicated to the development, manufacturing, and marketing of generic and proprietary injectable and sterile ophthalmic products, always considering the needs of healthcare providers and patients. Exela's primary objective is to provide high-quality, affordable products that not only make a difference in people's lives but also cater to the needs of the healthcare providers treating them. Exela Pharma Sciences focuses on developing products that enhance the patient or provider experience by addressing factors such as administration ease, improved safety profile, faster drug preparation, and reduced drug waste. Overall, the company aims to improve patient outcomes while simultaneously reducing healthcare costs. In September 2021, Exela received a Corporate Round investment with the participation of noteworthy investors including Memorial Healthcare System, Genesis Health, McLaren Health Care, Texas Health Resources, Henry Ford Health System, Saint Francis Health System, Premier Inc, Riverside Health System, Universal Health Services, and Baystate Health. Exela Pharma Sciences operates primarily in the Health Care, Health and Wellness, Manufacturing, and Pharmaceutical industries, with its headquarters located in the United States. By strategically focusing on products with high barriers to market entry, the company aims to leverage the Abbreviated New Drug Approval or 505(b)(2) regulatory pathway for its development and manufacturing initiatives. Overall, Exela's commitment to innovation and patient-centered solutions positions it as a compelling opportunity for potential investors in the healthcare and pharmaceutical sectors.